Detailed Narrative
Heart Attack Detection Progress
HeartBeam has made significant strides in its heart attack detection program, submitting its pre-submission to the FDA on the call date via the 510(k) pathway. Clinical validation efforts are ahead of schedule, with the ALIGN-ACS pilot study completing enrollment of 134 patients in under four months and its results accepted for presentation at TCT. The HEADSTART-ACS pilot study, a 500-patient study supported by the Indonesian government, has already surpassed 50% enrollment in less than three months. An upcoming JACC article will further demonstrate the accuracy of HeartBeam's algorithm in identifying heart attacks.
Product Platform & Intellectual Property
The company's core technology, utilizing tri-core 3D signal reconstruction, is protected by 25 issued patents worldwide. This proprietary technology enables the development of a platform with three distinct form factors: the Card for post-discharge monitoring, the Patch for emergency room and in-hospital monitoring, and the Remote Unit for access in remote locations, currently being used in Indonesia. The technology is clinically validated and FDA cleared for arrhythmic assessment, with ongoing efforts to expand into heart attack detection.
Commercial Strategy & Early Traction
HeartBeam's initial commercial launch is underway, focusing on the concierge vertical, which includes approximately 1.9 million patients, with hundreds of thousands identified as cardiac-oriented. The company has signed agreements in target markets including New York, Dallas, South Florida, and Southern California, with initial orders shipped and patients onboarding. A key learning has been to streamline workflow by integrating HeartBeam into new patient intake processes at concierge practices, which is expected to accelerate adoption and lead to an increasing magnitude of order flow by the end of Q3 FY26.
Financial Discipline & Runway Extension
The company demonstrated strong financial discipline in Q2 FY26, reducing net cash used in operating activities by 7% quarter-over-quarter to $3.3 million. This was achieved through tightly managed costs, efficiency gains, and executives electing to receive shares in lieu of cash for bonuses. Following an $11.5 million common stock financing in April 2026, HeartBeam reported $8.8 million in cash, cash equivalents, and restricted cash as of June 30, 2026, extending its cash runway further into 2027. The baseline operating cash flow is projected to be below $2.5 million per quarter by Q4 FY26, with full-year operating cash outflows expected to be below $14 million.
Future Innovations
HeartBeam continues to innovate, securing two new patents for future applications of its technology. One patent is for acoustic sensors, designed to provide insights into heart valve performance. The other is for fluid monitoring capabilities, utilizing impedance to detect fluid increases in patients, particularly beneficial for managing congestive heart failure and potentially reducing emergency room visits. These innovations highlight the platform's versatility and long-term growth potential beyond current indications.